Liraglutide vs Tirzepatide

This pair is the cleanest illustration of how cadence and receptor coverage compound. Liraglutide is a daily, single-receptor GLP-1 agonist; tirzepatide is a weekly, dual GLP-1 and GIP agonist. Either one of those changes alone would meaningfully shift the trial weight-loss numbers — together they explain why tirzepatide's average loss in SURMOUNT-1 (about 22.5 percent at 72 weeks) sits roughly four times higher than liraglutide's pivotal weight-loss readouts at the same general timeframe.

Mechanism is the structural divide. Liraglutide hits GLP-1 only and has a half-life around 13 hours. Tirzepatide hits GLP-1 plus GIP and has a half-life that lets weekly dosing make sense. The GIP arm is the part most readers ask about — it is the receptor that distinguishes tirzepatide from every previously approved molecule in this class, and it is the chemistry behind both the larger weight loss numbers and the slightly different early-weeks tolerance pattern compared to GLP-1-only molecules.

Logging the two molecules looks completely different in practice. Liraglutide is a daily ritual: same general window, same site rotation discipline, daily side-effect scoring during titration. Tirzepatide is a weekly calendar event with a longer tolerance arc per dose change. Pen versus vial geometry matters here too: liraglutide is most often administered from a pre-filled pen with fixed click increments, while tirzepatide in research-supplier form is reconstituted from a lyophilized vial and drawn into a U-100 insulin syringe.

Cost-per-dose math favors tirzepatide on the table above because its weekly cadence and higher per-dose milligrams stretch the example vial across more weeks. Real pharmacy prices vary, and the cost column should be read as a ratio rather than a budget number. The mg-to-units calculator linked below handles either molecule once your vial concentration is set, and the dose calculator shows how unit counts shift across the titration ladder for each.

For the Liraglutide vs Tirzepatide decision specifically, the calendar shape is what most readers underweight. Liraglutide's example vial is 6 mg drawn against 1.2 mg per dose at 7 doses per week. Tirzepatide's example vial is 10 mg drawn against 2.5 mg per dose at 1 dose per week. Those four numbers feed every column in the table above; change any one and the liraglutide vs tirzepatide comparison shifts with it.

Concentration in this pair: Liraglutide sits at 2.00 mg/mL on the example reconstitution; Tirzepatide sits at 5.00 mg/mL on its example. That single ratio is what determines how many U-100 syringe units a given dose of either molecule actually draws, so it is the first thing to confirm before treating any "Liraglutide vs Tirzepatide" unit number on the internet as authoritative.

Doses per vial in this matchup work out to roughly 5 for Liraglutide and 4 for Tirzepatide at the example dose sizes, with vial-duration windows near 0.7 weeks and 4.0 weeks respectively. Refill cadence follows directly from those windows, which is why the liraglutide vs tirzepatide pair shows up in planning conversations more than in pure mechanism conversations.

When readers compare Liraglutide against Tirzepatide, the Liraglutide-side mistakes that show up most in logs are: Failing to titrate the dose up slowly. Forgetting to rotate injection sites, leading to skin irritation. Injecting into a muscle instead of the subcutaneous fat layer. Miscalculating the dose when reconstituting a vial. Each of these gets amplified when a reader is also actively comparing against Tirzepatide, because muscle memory from one molecule's unit math leaks into the other.

Liraglutide question worth answering up front — What's the difference between Saxenda and Victoza? Saxenda and Victoza contain the same active ingredient, Liraglutide. However, they are used for different purposes and at different maximum doses. Saxenda is generally used for weight management and has a higher target dose (3.0 mg), while Victoza is primarily used for blood sugar management in type 2 diabetes and has a lower target dose (1.8 mg).

Liraglutide question worth answering up front — Why is Liraglutide injected daily instead of weekly? Liraglutide was designed to last for about 13 hours in the body. A once-daily injection ensures that there is a stable and effective level of the peptide in your system throughout the day. Other GLP-1 agonists, like Semaglutide, were later engineered to last even longer, allowing for a once-weekly dosing schedule.

On the Tirzepatide side of the Liraglutide vs Tirzepatide decision, the recurring mistakes are: Reusing the unit count from a previous vial after switching to a new vial that was reconstituted with a different diluent volume. Skipping the escalation date in the log, then being unable to answer when a dose change actually happened. Mixing up tirzepatide milligrams with semaglutide milligrams — the doses are typically much larger for tirzepatide and the math is not interchangeable. Underestimating doses-per-vial on a high-strength vial because the vial looks small even though it contains many weeks of supply. These are not generic dosing slips — they are the ones that compound when Tirzepatide is being logged in parallel with Liraglutide.

Tirzepatide question worth answering up front — How is tirzepatide reconstituted? By drawing a measured volume of bacteriostatic water and injecting it slowly into the lyophilized vial through the rubber stopper, then swirling — not shaking — until the powder fully dissolves. Diluent volume choices typically range from 2 to 5 mL depending on vial strength and preferred per-dose unit count.

Tirzepatide question worth answering up front — How many units of tirzepatide are in 2.5 mg? It depends on the concentration. On a 10 mg vial reconstituted with 2 mL of bacteriostatic water (5 mg per mL), 2.5 mg is exactly 50 units on a U-100 syringe. With 4 mL of diluent (2.5 mg per mL), the same dose is 100 units.